Understanding patients' perspective in the use of generic antiepileptic drugs: Compelling lessons for physicians to improve physician/patient communication

BMC Neurology

Volumn 9, Issue , 2009, Pages

  Liow, Kore ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GENERIC DRUG;

ARTICLE; BIOEQUIVALENCE; COST CONTROL; DOCTOR PATIENT RELATION; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EPILEPSY; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; LEGAL ASPECT; OUTCOME ASSESSMENT; PATIENT ADVOCACY; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PHARMACIST; PRESCRIPTION; ATTITUDE TO HEALTH; INTERPERSONAL COMMUNICATION; PATIENT EDUCATION; PATIENT SATISFACTION; PHARMACOKINETICS; PSYCHOLOGICAL ASPECT;

ANTICONVULSANTS; ATTITUDE TO HEALTH; COMMUNICATION; DRUGS, GENERIC; EPILEPSY; HUMANS; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PHYSICIAN-PATIENT RELATIONS; THERAPEUTIC EQUIVALENCY;

EID: 64049085402     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-9-11     Document Type: Article

References (51)

1. Duh MS Andermann F Paradis PE Weiner J Manjunath R Cremieux PY The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: The case of lamotrigine Dis Manag 2007, 10(4):216-225 10.1089/dis.2007.104649 17718660
2. Kramer G Biraben A Carreno M Guekht A de Haan GJ Jedrzejczak J Josephs D van Rijckevorsel K Zaccara G Current approaches to the use of generic antiepileptic drugs Epilepsy Behav 2007, 11(1):46-52 10.1016/ j.yebeh.2007.03.014 17537678
3. Heaney DC Sander JW Antiepileptic drugs: Generic versus branded treatments Lancet Neurol 2007, 6(5):465-468 10.1016/ S1474-4422(07)70105-9 17434101
4. Assessment: Generic substitution for antiepileptic medication. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 1990 40(11):1641-1643 2234417
5. Jobst BC Holmes GL Prescribing antiepileptic drugs: Should patients be switched on the basis of cost? CNS Drugs 2004, 18(10):617-628 10.2165/ 00023210-200418100-00001 15270592
6. Berg MJ Gross RA Physicians and patients percive that generic drug substitution of antiepileptic drugs can cause breakthrough seizures: results from a US survey Epilepsia 2006, 47(Suppl 4):55
7. Berg MJ Gross RA Tomaszewski KJ Zingaro WM Haskins LS Generic substitution in the treatment of epilepsy: Case evidence of breakthrough seizures Neurology 2008, 71(7):525-530 10.1212/ 01.wnl.0000319958.37502.8e 18695164
8. Guberman A Corman C Generic substitution for brand name antiepileptic drugs: A survey Can J Neurol Sci 2000, 27(1):37-43 10676586
9. Haskins LS Tomaszewski KJ Crawford P Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy Epilepsy Behav 2005, 7(1):98-105 10.1016/j.yebeh.2005.04.005 15961350
10. Wilner AN Therapeutic equivalency of generic antiepileptic drugs: results of a survey Epilepsy Behav 2004, 5(6):995-998 10.1016/ j.yebeh.2004.05.011 15582850
11. National Association of Boards of Pharmacy Survey of pharmacy law Mount Prospect, IL 2006
12. Berg MJ What's the problem with generic antiepileptic drugs?: A call to action Neurology 2007, 68(16):1245-1246 10.1212/ 01.wnl.0000262876.37269.8b 17438211
13. Borgheini G The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs Clin Ther 2003, 2(6):1578-1592 10.1016/S0149-2918(03)80157-1 12860486
14. Crawford P Feely M Guberman A Kramer G Are there potential problems with generic substitution of antiepileptic drugs? A review of issues Seizure 2006, 15(3):165-176 10.1016/j.seizure.2005.12.010 16504545
15. Danish Medicines Agency Guidelines and Forms http://www.dkma.dk/1024/ visUKLSArtikel.asp?artikelID=1586
16. Wolf P Political Campaign in Denmark Epilepsia 2007, 49(Suppl 7):6
17. Nielsen KA Dahl M Tommerup E Wolf P Comparative daily profiles with different preparations of lamotrigine: A pilot investigation Epilepsy Behav 2008, 13(1):127-130 10.1016/j.yebeh.2008.02.020 18406211
18. Besag FM Is generic prescribing acceptable in epilepsy? Drug Saf 2000, 23(3):173-182 10.2165/00002018-200023030-00001 11005701
19. Berg MJ Gross RA Haskins LS Zingaro WM Tomaszewski KJ Generic substitution in the treatment of epilepsy: Patient and physician perceptions Epilepsy Behav 2008, 13(4):693-699 18589000 10.1016/ j.yebeh.2008.06.001
20. Hartley R Aleksandrowicz J Ng PC McLain B Bowmer CJ Forsythe WI Breakthrough seizures with generic carbamazepine: A consequence of poorer bioavailability? Br J Clin Pract 1990, 44(7):270-273 2206824
21. MacDonald JT Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product Neurology 1987, 37(12):1885 3120036
22. Meyer MC Straughn AB Biopharmaceutical factors in seizure control and drug toxicity Am J Hosp Pharm 1993, 50(12 Suppl 5):S17-22 8122697
23. Bialer M Generic products of antiepileptic drugs (AEDs): Is it an issue? Epilepsia 2007, 48(10):1825-1832 10.1111/j.1528-1167.2007.01272.x 17850324
24. LeLorier J Duh MS Paradis PE Lefebvre P Weiner J Manjunath R Sheehy O Clinical consequences of generic substitution of lamotrigine for patients with epilepsy Neurology 2008, 70(22 Pt 2):2179-2186 10.1212/ 01.wnl.0000313154.55518.25 18505997
25. Privitera MD Generic antiepileptic drugs: Current controversies and future directions Epilepsy Currents 2008, 8(5):113-117 2566607 18852829 10.1111/j.1535-7511.2008.00261.x
26. Papsdorf TB Ablah E Ram S Sadler T Liow K Patient perception of generic antiepileptic drugs in the Midwestern United States Epilepsy Behav 2008 18845274
27. Kramer G Steinhoff BJ Feucht M Pfafflin M May TW Experience with generic drugs in epilepsy patients: An electronic survey of members of the German, Austrian and Swiss branches of the ILAE Epilepsia 2007, 48(3):609-611 10.1111/j.1528-1167.2007.01084_1.x 17346253
28. Liow K Barkley GL Pollard JR Harden CL Bazil CW Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy Neurology 2007, 68(16):1249-1250 10.1212/01.wnl.0000259400.30539.cc 17438213
29. Perucca E Albani F Capovilla G Bernardina BD Michelucci R Zaccara G Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs Epilepsia 2006, 47(Suppl 5):16-20 10.1111/j.1528-1167.2006.00871.x 17239100
30. Feely M Crawford P Kramer G Guberman A Risk management in epilepsy: generic substitution and continuity of supply The European Journal of Hospital Pharmacy Science 2005, 68(16):1249-1250
31. Wyllie E Pippenger CE Rothner AD Increased seizure frequency with generic primidone JAMA 1987, 258(9):1216-1217 10.1001/jama.258.9.1216 3626006
32. Mikati M Bassett N Schachter S Double-blind randomized study comparing brand-name and generic phenytoin monotherapy Epilepsia 1992, 33(2):359-365 10.1111/j.1528-1157.1992.tb02328.x 1547767
33. Oles KS Penry JK Smith LD Anderson RL Dean JC Riela AR Therapeutic bioequivalency study of brand name versus generic carbamazepine Neurology 1992, 42(6):1147-1153 1603340
34. Andermann F Duh MS Gosselin A Paradis PE Compulsory generic switching of antiepileptic drugs: High switchback rates to branded compounds compared with other drug classes Epilepsia 2007, 48(3):464-469 10.1111/ j.1528-1167.2007.01007.x 17346246
35. Dilorio C Faherty B Manteuffel B Learning needs of persons with epilepsy: A comparison of perceptions of persons with epilepsy, nurses and physicians J Neurosci Nurs 1993, 25(1):22-29 8445270
36. Lowes R Patient-centered care for better patient adherence Fam Pract Manag 1998, 5(3):46-47 51-44, 57 10178365
37. Schachter SC Antiepileptic drug therapy: General treatment principles and application for special patient populations Epilepsia 1999, 40(Suppl 9):S20-25 10.1111/j.1528-1157.1999.tb02090.x 10612358
38. Schachter SC Epilepsy: Quality of Life and Cost of Care Epilepsy Behav 2000, 1(2):120-127 10.1006/ebeh.2000.0049 12609141
39. Busch RL Generic carbamazepine and erythema multiforme: Generic-drug nonequivalency N Engl J Med 1989, 321(10):692-693 2770798
40. Sachdeo RC Belendiuk G Generic versus branded carbamazepine Lancet 1987, 1:8547 1432 10.1016/S0140-6736(87)90619-2 2884519
41. Hovinga CA Asato MR Manjunath R Wheless JW Phelps SJ Sheth RD Pina-Garza JE Zingaro WM Haskins LS Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: Survey of patients with epilepsy and physicians Epilepsy Behav 2008, 13(2):316-322 10.1016/j.yebeh.2008.03.009 18472303
42. UCB Compliance Survey: Analysis and Takeaways Conducted by Rosetta 2008
43. Wolf P Should newly diagnosed epilepsy be treated with generics? Nat Clin Pract Neurol 2008, 4(4):176-177 18301412
44. AED and Continuity of Supply: Consideration for Patients Conducted by UCB, Inc.; Transcripts from Patient Forum held March 30, 2008, Washington, D.C
45. The President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry Consumer Bill of Rights and Responsibilities. Report to the President of the United States Washington, DC: The President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry 1997
46. Sipkoff M The epilepsy battle in the war between brands and generics Manag Care 2008, 17(3):24-27 18447155
47. National Association of Boards of Pharmacy Survey of Pharmacy Laws. XIX Drug product selection laws 2006
48. Christensen TP Kirking DM Ascione FJ Welage LS Gaither CA Drug product selection: Legal issues J Am Pharm Assoc (Wash) 2001, 41(6):868-874 11765112
49. Vivian JC Generic-Substitution Laws US Pharmacist 2008, 33(6):30-34
50. Cassell DK Should generic substitution of antiepileptic drugs be restricted? Drug Topics Suppl 2007 Aug 6
51. Argumosa A Herranz JL The clinical and economic impact of generic drugs in the treatment of epilepsy Rev Neurol 2005, 41(1):45-49 15999330